Takeda Pharmaceutical Co Ltd ADR (TAK) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NYSE. Price $18.97 (-0.42%), Market cap $52.48B, P/E ratio 43.71, 52-week low–high $13.23 ~ $18.80.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva,
Financial statements, price targets, institutional (13F) holdings and related news for Takeda Pharmaceutical Co Ltd ADR are updated in real time on BlackAll Trade.
Takeda Pharmaceutical Co Ltd ADR trades at $18.97 (-0.42%). Real-time quotes and charts are available on BlackAll Trade.
Takeda Pharmaceutical Co Ltd ADR has a market cap of about $52.48B. Its P/E ratio is 43.71.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical